GXMC
SIOX

Global X Management Company’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Global X Management Company’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-193
Closed -$2K – 1203
2018
Q1 		$2K Buy
193
+49
+34% +$787 ﹤0.01% 1137
2017
Q4 		$6K Buy
144
+32
+29% +$1.44K ﹤0.01% 1049
2017
Q3 		$6K Buy
112
+16
+17% +$2.7K ﹤0.01% 1111
2017
Q2 		$18K Buy
96
+47
+96% +$8.24K ﹤0.01% 1171
2017
Q1 		$6K Buy
49
+3
+7% +$314 ﹤0.01% 1172
2016
Q4 		$5K Hold
46
– – ﹤0.01% 1062
2016
Q3 		$5K Hold
46
– – ﹤0.01% 1069
2016
Q2 		$5K Buy
+46
New +$4.6K ﹤0.01% 936
2015
Q4 		– Sell
-127
Closed -$13K – 972
2015
Q3 		$13K Buy
+127
New +$14.9K ﹤0.01% 544

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Global X Management Company's SIOX Position: Q2 2018 in Review

Global X Management Company sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 193 shares — an estimated $2K sold.

Global X Management Company first reported a position in SIOX in Q3 2015 and held it in 9 quarters. The position peaked at $18K in Q2 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

  • Global X Management Company reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Global X Management Company sold 193 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $2K.
  • Global X Management Company first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 9 quarters.
  • Global X Management Company's Sio Gene Therapies Inc. Common Stock position peaked at $18K in Q2 2017.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on Global X Management Company's 13F filing for Q2 2018, filed 16 Aug 2018.